Skip to main content

PACS and RIS Market To Witness Substantial Growth Due To Growing Popularity of PACS around the World

 


Overview:

A PACS system is a database of medical images and other medical information. It is generally stored in an RIS, though radiologists may choose to view the results directly in PACS. Cloud PACS solutions, however, allow radiologists to access even more information. Moreover, many providers boast of being able to integrate PACS with RIS. However, they are unable to quantify the integration time. RIS and PACS solutions are designed to facilitate interoperability among imaging devices. This is done by creating a standardized communication interface based on DICOM standards. The RIS acts as a master system that provides image management and move control functions. 

Market Dynamics:

The popularity of PACS is growing all over the world and this is anticipated to propel growth of the global PACS and RIS market over the forecast period. PACS help to reduce the physical as well as time barriers linked to regular film-based retrieval, display and distribution of images. For instance, in August 2021, PaxeraHealth, developer of PACS/RIS announced to launch its novel product called PaxexaUltima 8th Generation, which is an AI-based imaging platform that provides AI algorithms for analyzing large data sets.

However, risk of cyber-attacks leading to growing concerns about safety of data in healthcare is likely to obstruct growth of the global PACS and RIS market over the forecast period.

Impact of COVID-19:

The coronavirus outbreak in China affected several industries around the world. Due to the virus outbreak many countries announced nationwide lockdowns. Several market activities including manufacturing, supply of raw materials and distribution activities were disrupted throughout this period. The demand for various products declined during the pandemic which adversely affected growth of several markets including the one in discussion. However, as many countries are lifting lockdown regulations, the market is likely to regain growth.

Key Takeaways:

·         The global PACS and RIS market is expected to grow with a CAGR of 6.8% over the forecast period due to growing number of health care facilities along with products of high value such as orthopedic PACS, cardiology PACS, and more. For instance, in July 2022, The Royal Orthopedic Hospital NHS Foundation Trust announced to deploy a novel cloud-based PACS to offer radiologist intelligent productivity tools.

·         North America is anticipated to witness substantial growth in the global PACS and RIS market over the forecast period. This is due to growing demand for health care and increasing government initiatives for R&D across the region.

·         Major players active in the global PACS and RIS market are Novarad, GENERAL ELECTRIC COMPANY, Cerner Corporation, Koninklijke Philips N.V., ScImage, Inc., FUJIFILM Holdings, PACSHealth, LLC, McKesson Corporation, IBM, Siemens Healthcare Private Limited, INFINITT North America Inc., Agfa-Gevaert Group, Avreo, and Allscripts Healthcare, LLC.

 

 

Labels:

Comments

Post a Comment

Popular posts from this blog

The Global Pressure Bandages Market Is Witnessing High Growth Owing To the Increasing Incidence of Surgical Processes in the World

  Market Overview: During a medical emergency, a pressure bandage is used to apply pressure to an area of the body to control bleeding and swelling. There are a variety of types of pressure bandages that can be used for different purposes. The bandage is made up of several parts, including an air bladder, a pad, a closure bar, and an applicator. A pressure bandage can be applied to wounds at any location on the body. This type of dressing is useful in treating various conditions, including gunshot wounds. It can also be used for a temporary holding of a hernia. The bandage is usually vacuum-sealed, so it's easier to carry. Competitive Landscape: Major players operating in the global pressure bandages market include ConvaTec Group PLC., Cardinal Health, 3M, B. Braun Melsungen AG, Lohmann & Rauscher GmbH & Co. KG, Mölnlycke Health Care AB, Smith & Nephew plc., Paul Hartmann AG, and Essity (BSN medical GmbH). Key Market Drivers: Increasing developments by key pla...
Post a Comment
Read more

Increasing Incidences of Infectious Diseases to Augment the Antibacterial Drugs Market Growth

  Antibacterial drugs are widely used to treat and prevent infectious diseases and are categorized into seven major classes, such as β-Lactams, phenicols, macrolides, quinolones, sulfonamides, tetracyclines, and aminoglycosides, based on their molecular structure. Antibacterial drugs destroy or slow down the growth of bacteria. These medications are also used to treat urinary infections caused by S. aureus, E. coli, Streptococcus pyogenes, and other bacterial infections. They include a range of powerful drugs used to treat diseases caused by bacteria. Antibiotics cannot treat viral infections, such as cold, flu, and most coughs. Antibacterial drugs play a major role in advanced healthcare, as they are widely used to treat infectious diseases, such as tuberculosis, malaria, typhoid, leprosy, hepatitis B, HIV/AIDS, and others. Thus, there is an increasing demand for antibacterial drugs worldwide.  
Post a Comment
Read more

Fc Protein and Glycoengineered Antibodies Market Is Booming Worldwide 2023-2028

  Global Fc Protein and Glycoengineered Antibodies Market Drivers Key players in the market are focusing on research and development activities and receiving approvals from regulatory bodies, which are expected to boost the global Fc protein and glycoengineered antibodies market growth over the forecast period. For instance, in 2016, Genentech Inc. received approval from the U.S. Food and drug Administration (U.S. FDA) for Tecentriq (Atezolizumab). It is being used for the treatment of urothelial carcinoma. In March 2019, Tecentriq received its second approval from the U.S. FDA for the treatment of small lung cancer. Furthermore, in November 2017, TG Therapeutics, Inc. began its clinical trial of Ublituximab for the treatment of multiple sclerosis. It is currently in third phase of its clinical trial. Factors such as increasing product approvals and robust pipeline are expected to drive the global fc protein and glycoengineered antibodies market growth.  Increasing preva...
Post a Comment
Read more